UY32644A - Compuesto anticancerígeno y composición farmacéutica que lo contiene - Google Patents

Compuesto anticancerígeno y composición farmacéutica que lo contiene

Info

Publication number
UY32644A
UY32644A UY0001032644A UY32644A UY32644A UY 32644 A UY32644 A UY 32644A UY 0001032644 A UY0001032644 A UY 0001032644A UY 32644 A UY32644 A UY 32644A UY 32644 A UY32644 A UY 32644A
Authority
UY
Uruguay
Prior art keywords
compound
antichanceriginal
pharmaceutical composition
composition containing
levogyrous
Prior art date
Application number
UY0001032644A
Other languages
English (en)
Inventor
Jean-Christophe Carry
Combeau Cecile
Clerc Francois
Schio Laurent
Michel Cheve
Sylvie Gontier
Krick Alain
Lachaud Sylvette
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY32644A publication Critical patent/UY32644A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Abstract

La invención se refiere al compuesto de fórmula (I): más particularmente en su forma levógira (Ia), particularmente la que presenta el poder rotatorio [a(alfa)]D=-38,6+0,7 a una concentración de 0,698 mg/ml en metanol. El compuesto puede existir en forma de base o de una sal de adición a un ácido, particularmente un ácido farmacéuticamente aceptable.Este compuesto es un inhibidor selectivo de las quinasa Aurora A y B.Puede utilizarse como agente anticancerígeno.
UY0001032644A 2009-05-18 2010-05-18 Compuesto anticancerígeno y composición farmacéutica que lo contiene UY32644A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902392A FR2945535B1 (fr) 2009-05-18 2009-05-18 Compose anticancereux et composition pharmaceutique le contenant

Publications (1)

Publication Number Publication Date
UY32644A true UY32644A (es) 2010-12-31

Family

ID=40973187

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032644A UY32644A (es) 2009-05-18 2010-05-18 Compuesto anticancerígeno y composición farmacéutica que lo contiene

Country Status (35)

Country Link
US (2) US9073917B2 (es)
EP (1) EP2432766B1 (es)
JP (1) JP5656981B2 (es)
KR (1) KR20120032483A (es)
CN (1) CN102459193B (es)
AR (1) AR076686A1 (es)
AU (1) AU2010251013B2 (es)
BR (1) BRPI1012201A2 (es)
CA (1) CA2762233C (es)
CL (1) CL2011002930A1 (es)
CO (1) CO6400138A2 (es)
CY (1) CY1114850T1 (es)
DK (1) DK2432766T3 (es)
EA (1) EA021084B1 (es)
ES (1) ES2430989T3 (es)
FR (1) FR2945535B1 (es)
HK (1) HK1167388A1 (es)
HR (1) HRP20130959T1 (es)
IL (1) IL216361A0 (es)
JO (1) JO2852B1 (es)
MA (1) MA33356B1 (es)
ME (1) ME01542B (es)
MX (1) MX2011012356A (es)
MY (1) MY152995A (es)
NZ (1) NZ596464A (es)
PL (1) PL2432766T3 (es)
PT (1) PT2432766E (es)
RS (1) RS53002B (es)
SG (1) SG176169A1 (es)
SI (1) SI2432766T1 (es)
SM (1) SMT201400005B (es)
TW (1) TWI441822B (es)
UY (1) UY32644A (es)
WO (1) WO2010133794A1 (es)
ZA (1) ZA201108447B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
ES2719776T3 (es) * 2012-10-12 2019-07-16 Broad Inst Inc Inhibidores de GSK3 y métodos de uso de los mismos
TW201609751A (zh) 2014-07-01 2016-03-16 武田藥品工業股份有限公司 雜環化合物
SG11201909115WA (en) 2017-04-05 2019-10-30 Broad Inst Inc Tricyclic compounds as glycogen synthase kinase 3 (gsk3) inhibitors and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001036422A1 (en) 1999-11-19 2001-05-25 Abbott Laboratories Tricyclic dihydropyrimidine potassium channel openers
CN1630656A (zh) 2001-02-02 2005-06-22 三菱制药株式会社 二氢吡唑并吡啶化合物及其制药用途
US7037902B2 (en) 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
AU2004264834A1 (en) * 2003-06-13 2005-02-24 Zentaris Gmbh Compounds having inhibitive activity of phosphatidylinositol 3-kinase and methods of use thereof
DK1746097T3 (da) * 2005-07-20 2010-05-25 Aventis Pharma Sa 1,4-dihydropyridin-kondenserede heterocykliske ringe, fremgangsmåde til fremstilling af disse, anvendelse og sammensætninger, der indeholder dem
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant

Also Published As

Publication number Publication date
PL2432766T3 (pl) 2013-12-31
AU2010251013B2 (en) 2015-08-20
JP2012527436A (ja) 2012-11-08
US20150266877A1 (en) 2015-09-24
CO6400138A2 (es) 2012-03-15
AU2010251013A1 (en) 2011-12-08
EP2432766B1 (fr) 2013-07-17
RS53002B (en) 2014-04-30
TW201100418A (en) 2011-01-01
MX2011012356A (es) 2011-12-14
EP2432766A1 (fr) 2012-03-28
JO2852B1 (en) 2015-03-15
JP5656981B2 (ja) 2015-01-21
EA021084B1 (ru) 2015-04-30
CL2011002930A1 (es) 2012-06-29
SMT201400005B (it) 2014-03-07
US20120220621A1 (en) 2012-08-30
HRP20130959T1 (hr) 2013-11-22
AR076686A1 (es) 2011-06-29
SG176169A1 (en) 2011-12-29
EA201171429A1 (ru) 2012-05-30
ME01542B (me) 2014-04-20
CN102459193B (zh) 2014-08-27
MY152995A (en) 2014-12-31
US9221817B2 (en) 2015-12-29
CA2762233A1 (fr) 2010-11-25
SI2432766T1 (sl) 2013-11-29
CN102459193A (zh) 2012-05-16
DK2432766T3 (da) 2013-10-28
TWI441822B (zh) 2014-06-21
HK1167388A1 (en) 2012-11-30
FR2945535B1 (fr) 2011-06-10
US9073917B2 (en) 2015-07-07
WO2010133794A1 (fr) 2010-11-25
CA2762233C (fr) 2017-11-28
MA33356B1 (fr) 2012-06-01
KR20120032483A (ko) 2012-04-05
FR2945535A1 (fr) 2010-11-19
PT2432766E (pt) 2013-10-23
BRPI1012201A2 (pt) 2016-04-05
ES2430989T3 (es) 2013-11-22
NZ596464A (en) 2014-01-31
ZA201108447B (en) 2013-01-30
IL216361A0 (en) 2012-01-31
CY1114850T1 (el) 2016-12-14

Similar Documents

Publication Publication Date Title
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
DOP2012000011A (es) Formulacion farmaceutica
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
SV2009003281A (es) Inhibidores espiro cetona de acetil-coa carboxilasa.0
MA33803B1 (fr) Inhibiteur de bromodomaine de benzodiazépine
EA018193B3 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
ECSP077402A (es) Derivados de 2-amido-4-feniltiazol, su preparación y su aplicación en terapéutica
MA32776B1 (fr) Inhibiteurs de l'akt et de la p70 s6 kinase
ATE485261T1 (de) Salicylsäurederivate
ECSP088689A (es) NOVEDOSAS 11ß-HIDROXIANDROSTA-4-EN-3-ONAS
AR078142A1 (es) Compuestos inhibidores heteroarilicos biciclicos de pde4, las composiciones farmaceuticas que los contienen y el uso de los mismos para la preparacion de medicamentos.
CR20110209A (es) Composición farmacéutica sólida
UY32644A (es) Compuesto anticancerígeno y composición farmacéutica que lo contiene
SG158091A1 (en) Imidazoazepinone compounds
ECSP11010856A (es) Composición farmacéutica sólida
ATE537816T1 (de) Leflunomid enthaltende pharmazeutische zusammensetzungen
UY32894A (es) Derivados de 5-fenil-pirazolopiridina, su preparación y su aplicación en terapéutica
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
UA105034C2 (uk) Фармацевтична комбінація 5-фторурацилу і похідного 1,4-дигідропіридину та її застосування в лікуванні раку
GT200600132A (es) Una oxindoloxazolidinona como agente antibacteriano
TH135249A (th) สารประกอบตัวยับยั้งออโรราต้านมะเร็งและองค์ประกอบทางเภสัชกรรมที่มีสารดังกล่าว, กระบวนการและอินเทอร์มิเดียทสำหรับการเตรียมสารเหล่านั้น
TH135249B (th) สารประกอบตัวยับยั้งออโรราต้านมะเร็งและองค์ประกอบทางเภสัชกรรมที่มีสาร ดังกล่าว, กระบวนการและอินเทอร์มิเดียทสำหรับการเตรียมสารเหล่านั้น
HN2008000426A (es) Compuestos de pirimidina amida como inhibidores de pgds

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181129